| Bioactivity | Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research[1]. |
| Invitro | Antitumor agent-92 (化合物 11c; 2-8 μM; 48 小时) 诱导 HepG2 和 SMMC-7721 细胞凋亡，特别是在高浓度时[1]。 Antitumor agent-92 (2-8 μM; 48 小时) 可以在 HepG2 和 SMMC-7721 细胞中诱导 G0/G1 周期停滞[1]。 Antitumor agent-92 (2-8 μM; 48 小时) 上调 P21 并下调 Cdc2 p34 和 CDK4[1]。 Apoptosis Analysis[1] Cell Line: |
| Name | Antitumor agent-92 |
| Formula | C33H41NO10 |
| Molar Mass | 611.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jichong Li, et al. Synthesis and Structure-Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells. J Nat Prod. 2023 Feb 24;86(2):290-306. |